# EDGAR Filing Document

**Accession Number:** 0001991792
**File Stem:** 0001193125-26-261670
**Filing Date:** 2026-6
**Character Count:** 7108
**Document Hash:** 85155941784bb225b3f23d853aca459e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-261670.hdr.sgml**: 20260608

**ACCESSION NUMBER**: 0001193125-26-261670

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260604

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260608

**DATE AS OF CHANGE**: 20260608

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CG Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001991792
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 371611499
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41925
- **FILM NUMBER:** 261072523

**BUSINESS ADDRESS:**
- **STREET 1:** 3000 PEGASUS PARK DRIVE
- **STREET 2:** SUITE 1640
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75247
- **BUSINESS PHONE:** (949) 409-3700

**MAIL ADDRESS:**
- **STREET 1:** 3000 PEGASUS PARK DRIVE
- **STREET 2:** SUITE 1640
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75247

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 4, 2026

## CG Oncology, Inc.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41925** | **37-1611499** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **3000 Pegasus Park Drive** |  |
| **Suite 1640** |  |
| **Dallas, Texas** | **75247** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (949) 409-3700

#### N/A

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $0.0001 per share | CGON | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 4, 2026, CG Oncology, Inc. (the "**Company**") held its 2026 Annual Meeting of Stockholders (the "**Annual Meeting**"). As of April 7, 2026, the record date for the Annual Meeting, 88,009,980 shares of common stock were outstanding and entitled to vote at the Annual Meeting. The following tables set forth the final results of the voting for the matters voted upon at the Annual Meeting. These matters are described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2026 (the "**Proxy Statement**").

*Proposal 1: Election of Directors* 

The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Shares<br>Voted For** | **Shares<br>Voted Withhold** | **Broker<br>Non-Votes** |
| **Name of Directors Elected** |  |  |  |
| Christina Rossi | 67531501 | 89825 | 16216685 |
| Victor Tong, Jr. | 62401874 | 5219452 | 16216685 |

---

*Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm* 

The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

---

| | | |
|:---|:---|:---|
| **Shares<br>Voted For** | **Shares<br>Voted Against** | **Abstentions** |
| 83711522 | 4103 | 122386 |

---

*Proposal 3: Advisory Vote on Executive Compensation* 

The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Shares<br>Voted For** | **Shares<br>Voted Against** | **Abstentions** | **Broker Non-Votes** |
| 65894959 | 1603011 | 123356 | 16216685 |

---

*Proposal 4: Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation* 

The Company's stockholders indicated, on an advisory basis, their preference for the frequency of stockholder advisory votes on the compensation of the Company's named executive officers. The final voting results are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **1 Year** | **2 Years** | **3 Years** | **Abstentions** | **Broker Non-Votes** |
| 66962791 | 4269 | 537270 | 116996 | 16216685 |

---

Consistent with these results, the Company determined that future stockholder advisory votes on named executive officer compensation will be held every year until the next required advisory vote on the frequency of stockholder advisory votes on named executive officer compensation.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CG Oncology, Inc.** | **CG Oncology, Inc.** |
| Date: June 8, 2026 | By: | /s/ Josh Patterson |
|  | Name: Josh Patterson | Name: Josh Patterson |
|  | Title: General Counsel, Chief Compliance Officer and Secretary | Title: General Counsel, Chief Compliance Officer and Secretary |

---